406488-71-9Relevant academic research and scientific papers
(2R)-2-ethylchromane-2-carboxylic acids: Discovery of novel PPARα/γ dual agonists as antihyperglycemic and hypolipidemic agents
Koyama, Hiroo,Miller, Daniel J.,Boueres, Julia K.,Desai, Ranjit C.,Jones, A. Brian,Berger, Joel P.,MacNaul, Karen L.,Kelly, Linda J.,Doebber, Thomas W.,Wu, Margaret S.,Zhou, Gaochao,Wang, Pei-Ran,Ippolito, Marc C.,Chao, Yu-Sheng,Agrawal, Arun K.,Franklin, Ronald,Heck, James V.,Wright, Samuel D.,Moller, David E.,Sahoo, Soumya P.
, p. 3255 - 3263 (2007/10/03)
A series of chromane-2-carboxylic acid derivatives was synthesized and evaluated for PPAR agonist activities. A structure-activity relationship was developed toward PPARα/γ dual agonism. As a result, (2R)-7-{3-[2-chloro-4-(4-fluorophenoxy)phenoxy]propoxy}
Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
-
, (2008/06/13)
A class of benzopyrancarboxylic acid derivatives comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
